Following CE Mark clearance, Medtronic announced introducing the Prevail drug-coated balloon (DCB) catheter in Europe. Prevail DCB is utilized during percutaneous coronary intervention treatments to repair constricted or obstructed coronary arteries in patients with coronary artery disease. As part of the Prevail DCB, paclitaxel is used to treat small vessel disease, de novo lesions, and restenosis inside a stent. PowerTrac, the same technology utilized in the Medtronic Resolute Onyx drug-eluting stent delivery mechanism, is said to offer better efficacy and push capacity over the prior In.Pact Falcon technology, allowing more control for complicated anatomies, according to the firm. In addition, the crossing profile is low in Prevail DCB.
Dr. Latib A, lead principal investigator and Section Head of Interventional Cardiology and Medical Director of Structural Heart Interventions at Montefiore Medical Center, New York, states that as more patients with complicated lesions are treated, having a DCB that is widely transferable across a range of vessels and uses a medication that absorbs rapidly into the artery becomes more critical. For interventional cardiologists using DCB technology, Prevail DCB is an excellent choice to treat their patients because of its outstanding transferability and solid safety profile supported by clinical data.
The data presented at the 2020 PCR e-Course conference confirms that the safety and effectiveness of Prevail drug-coated balloon are better than the previous-generation In.Pact Falcon DCB clinical program, which was established by the PREVAIL research. The findings of Prevail DCB as per PREVAIL study are as follows:
At six months, favorable late loss (0.05 ± 0.44 mm).
The performance was exceptional in patients with small vessel disease, complex lesions, and restenosis inside a stent.
The safety profile is strong with no target vessel myocardial infarction, stent thrombosis, or cardiac death and target lesion revascularization was low (6%).